↓ Skip to main content

Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease

Overview of attention for article published in BMC Ophthalmology, March 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
36 Mendeley
Title
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
Published in
BMC Ophthalmology, March 2015
DOI 10.1186/s12886-015-0001-7
Pubmed ID
Authors

Marcel N Menke, Carsten Framme, Mathias Nelle, Markus R Berger, Veit Sturm, Sebastian Wolf

Abstract

Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevacizumab is still very controversial. We report the outcome of 6 eyes of 4 premature infants with ROP stage 3 plus disease treated with ranibizumab monotherapy. Six eyes of 4 premature infants with threshold ROP 3 plus disease in zone II, were treated with one intravitreal injection of 0.03 ml ranibizumab. No prior laser or other intravitreal therapy was done. Fundus examination was performed prior to the intervention and at each follow-up visit. Changes in various mean vital parameters one week post intervention compared to one week pre-intervention were assessed. The gestational age (GA) of patient 1, 2, 3, and 4 at birth was 24 5/7, 24 5/7, 24 4/7, and 26 1/7 weeks, respectively. The birth weight was 500 grams, 450 grams, 665 grams, and 745 grams, respectively. The GA at the date of treatment ranged from 34 3/7 to 38 6/7 weeks. In one infant, upper air way infection was observed 2 days post injection of the second eye. Three eyes required paracentesis to reduce the intraocular pressure after injection and to restore central artery perfusion. After six months, all eyes showed complete retinal vascularisation without any signs of disease recurrence. Treatment of ROP 3 plus disease with intravitreal ranibizumab was effective in all cases and should be considered for treatment. One infant developed an upper air way infection suspicious for nasopharyngitis, which might be a possible side effect of ranibizumab. Another frequent complication was intraocular pressure rise after injection. More patients with longer follow-up duration are mandatory to confirm the safety and efficacy of this treatment. NCT02164604 ; Date of registration: 13.06.2014.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Canada 1 3%
Unknown 34 94%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 6 17%
Professor > Associate Professor 6 17%
Researcher 5 14%
Student > Doctoral Student 4 11%
Unspecified 4 11%
Other 11 31%
Readers by discipline Count As %
Medicine and Dentistry 25 69%
Unspecified 7 19%
Biochemistry, Genetics and Molecular Biology 1 3%
Computer Science 1 3%
Agricultural and Biological Sciences 1 3%
Other 1 3%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2015.
All research outputs
#7,856,777
of 13,712,456 outputs
Outputs from BMC Ophthalmology
#239
of 824 outputs
Outputs of similar age
#96,761
of 215,708 outputs
Outputs of similar age from BMC Ophthalmology
#1
of 1 outputs
Altmetric has tracked 13,712,456 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 824 research outputs from this source. They receive a mean Attention Score of 2.3. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 215,708 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them